Trial Profile

Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RLYB116 in Healthy Participants

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 04 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs RLYB 116 (Primary)
Indications Antiphospholipid syndrome; Myasthenia gravis; Paroxysmal nocturnal haemoglobinuria
Focus Adverse reactions; First in man

Most Recent Events

02 Dec 2024 Results presented in a Rallybio media release
02 Dec 2024 According to a Rallybio media release, today announced results of new biomarker characterization analyses and data from the recently completed manufacturing process enhancements for RLYB116.
12 Aug 2024 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com